{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:11:05Z","timestamp":1773418265257,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>As emicizumab shares no sequence homology with factor VIII (FVIII), in patients with haemophilia A, haemostasis can be restored irrespective of the presence of FVIII inhibitors. Emicizumab, therefore, substantially improved previously available prophylactic options. This study aims to evaluate the cost\u2010effectiveness of using emicizumab prophylaxis therapy compared to recombinant FVIII (rFVIII) prophylaxis for the treatment of severe haemophilia A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model from a Chinese healthcare system perspective using annual cycles was constructed to evaluate the lifelong costs and effectiveness. All patients started at age zero in a non\u2010inhibitor state, treated with either emicizumab or rFVIII prophylaxis. On\u2010demand rFVIII was given upon breakthrough bleeding for both groups. A part of severe patients developed FVIII inhibitors resulting from on\u2010demand treatment. For patients with inhibitors, those previously treated with rFVIII prophylaxis switched to a recombinant activated factor VII (rFVIIa) on\u2010demand only therapy, whereas those previously on emicizumab kept the same prophylactic regimen with rFVIIa for breakthrough bleeds. One immune tolerance induction (ITI) was allowed to eradicate inhibitors. Model inputs, including utility values, bleeding rates, adverse event rates and the success rate of ITI were from HAVEN 1 and 3 trials and the other literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results of both the 0\u201312 age group and lifetime simulations demonstrated a dominant economic advantage of emicizumab prophylaxis over rFVIII prophylaxis therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severe haemophilia A patients treated by emicizumab prophylaxis can benefit both patients\u2019 QoL and economic outcomes compared to those treated by rFVIII prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70209","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:16:27Z","timestamp":1769768187000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lifetime Cost\u2010Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis"],"prefix":"10.1111","volume":"32","author":[{"given":"Han","family":"Bao","sequence":"first","affiliation":[{"name":"Sun Yat\u2010Sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"B\u00fchrer","sequence":"additional","affiliation":[{"name":"F. Hoffmann La Roche Ltd  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Lin","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Anhui Medical University  Hefei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xia","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceuticals Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuze","family":"Jin","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceuticals Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Xuan","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010Sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"7","key":"e_1_2_10_2_1","first-page":"579","article-title":"Guidelines for the Diagnosis and Treatment of Hemophilia A (2022 Edition)\u201d [in Chinese]","volume":"20","author":"National Health Commission of the People's Republic of China","year":"2022","journal-title":"Clinical Education of General Practice"},{"issue":"4","key":"e_1_2_10_3_1","first-page":"265","article-title":"Chinese Guidelines for the Treatment of Hemophilia (2020 Edition) [in Chinese]\u201d","volume":"41","author":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Hemophilia Collaboration Group","year":"2020","journal-title":"Chinese Journal of Hematology"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2015.10.008"},{"key":"e_1_2_10_5_1","first-page":"32","article-title":"Medical Insurance and Management Analysis of Hemophilia \u2014Based on the Experience of Shenzhen [in Chinese]\u201d","volume":"1","author":"Dong Z. H.","year":"2018","journal-title":"Chinese Medical Insurance"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010118153"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(19)30054\u20107"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670"},{"key":"e_1_2_10_11_1","unstructured":"Hemophilia Home of China Report on Treatment Patterns and Disease Burden in Hemophilia Patients in China[in Chinese] (Center for Pharm Policy & Economics Tianjin University) (2024)."},{"key":"e_1_2_10_12_1","unstructured":"General Administration of Sport of China 2014 National Physical Fitness Monitoring Bulletin[in Chinese](2015) https:\/\/www.sport.gov.cn\/n315\/n329\/c216784\/content.html."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201010\u2010050435"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12121"},{"key":"e_1_2_10_15_1","unstructured":"Office of the Leading Group of the State Council for the Seventh National Population Census The National Mortality Statistics by Age and Gender[in Chinese](2021) https:\/\/www.stats.gov.cn\/sj\/pcsj\/rkpc\/7rp\/zk\/indexch.htm."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1649378"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02235.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201008\u2010369132"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12774"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102516.2003.00783.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.992267"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.016"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28474"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20090"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1405816"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1258\/rsmacta.43.5.528"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13120"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2021.2020.0717"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14723"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:35:08Z","timestamp":1773408908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/hae.70209"],"URL":"https:\/\/doi.org\/10.1111\/hae.70209","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}